Aktieanalys

Cantargia: Positive CAN10 MAD Data - Redeye

{newsItem.title}

Redeye Publicerad: 05 Mar 11:46

Redeye is positive about the multiple ascending dose data being in line with previous single ascending dose data. The FDA advice from a pre-IND meeting supports future development in HS.

Länk till analysen i sin helhet: https://www.redeye.se/research/1086916/cantargia-positive-can10-mad-data?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt